Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort

Seok-Hyung Won; Soyeon Ahn; Eunjeong Ji; Jung Wee Park; Jin-Kak Kim; Young-Kyun Lee

doi:10.3346/jkms.2020.35.e193

Journal List > J Korean Med Sci > v.35(25) > 1146042

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Won, Ahn, Ji, Park, Kim, and Lee: Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort

Original Article

Musculoskeletal Disorders, Rehabilitation & Sports Medicine

Journal of Korean Medical Science 2020; 35(25): e193.

Published online: 18 May 2020

DOI: https://doi.org/10.3346/jkms.2020.35.e193

Hip and Subtrochanteric or Femoral Shaft Fractures after Bisphosphonate Use in Korean Women, Using Korean National Sample Cohort

Seok-Hyung Won^1,^*

, Soyeon Ahn^2,^*

, Eunjeong Ji²

, Jung Wee Park¹

, Jin-Kak Kim¹

, Young-Kyun Lee¹

¹Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.

²Division of Statistics, Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, Korea.

Address for Correspondence: Young-Kyun Lee, MD. Department of Orthopedic Surgery, Seoul National University Bundang Hospital, 82 Gumi-ro 173-beon-gil, Bundang-gu, Seongnam 13620, Republic of Korea. ykleemd@gmail.com

Equal contributor:

^*Seok-Hyung Won and Soyeon Ahn contributed equally to this work.

Received 7 April 2020 Accepted 27 April 2020

The Korean Academy of Medical Sciences

(open-access, https://creativecommons.org/licenses/by-nc/4.0/):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

Concern about bisphosphonate-associated subtrochanteric and femoral shaft (ST/FS) fractures has been raised. However, its real risk is still debatable, because there is no study to estimate risk and benefit of bisphosphonate. The objective of this study was to evaluate the risk of typical hip fractures and ST/FS fractures among bisphosphonate users using nationwide database.

Methods

We performed a retrospective cohort study using National Health Insurance Service-National Sample Cohort. We evaluated occurrence of the ST/FS and femoral neck and intertrochanteric (FN/IT) fractures among female bisphosphonate new users. Incidence rate of ST/FS and FN/IT fractures were compared between long-term users (≥ 1 year) and short-term users (< 1 year). Number needed to harm (NNH) for ST/FS and number needed to treat (NNT) for typical hip fracture were analyzed.

Results

Among 46,420 bisphosphonate users, we identified 14,689 long-term users and 21,840 short-term users. During the study period, 61 long-term users and 36 short-term users had ST/FS fractures, while 204 long-term users and 511 short-term users had FN/IT fractures. The long-term user showed higher incidence rate of ST/FS fractures (67.1/100,000 person-years; 95% confidence interval [CI], 50.3–83.9) comparing with 31.2/100,000 person-years (95% CI, 21.0–41.4) in the short-term users. The incidence rate of FN/IT fractures was 225.5/100,000 person-years (95% CI, 194.6–256.5) in the long-term users and 448.6/100,000 person-years (95% CI, 409.7–487.5) in the short-term users. The NNH for ST/FS was 400, while the NNT for typical hip fracture was 105.

Conclusion

Our study suggested that physicians keep the significant benefit of bisphosphonate to prevent typical hip fracture in mind, even the concerns about bisphosphonate-associated ST/FS fractures.

Graphical Abstract

Keywords: Atypical Femur Fracture, Osteoporosis, Bisphosphonate, Hip Fracture, Fragility Fracture

INTRODUCTION

Osteoporosis is one of the most important healthcare concerns and results in osteoporotic fractures in elderly population.1 2 Osteoporotic fractures lead to the decreased mobility, activity and quality of life in these population.3 4

Bisphosphonates, one of potent anti-resorptive agents, have been recommended to treat osteoporosis and to prevent osteoporotic fractures.2 5

Recent studies have reported that long-term use of bisphosphonates was associated with the increased risk of atypical femoral fractures (AFFs).6 7 These fractures occur spontaneously or after minimal trauma at the subtrochanteric region or femoral shaft (ST/FS).8 9 They are often proceeded by a prodromal pain, and have radiographic features of an insufficiency fracture; lateral cortical thickening and transverse fracture pattern,10 and are associated with high rates of non-union and reoperation.11 12 13 14 15 16

Based on several epidemiologic studies with large scale cohorts, the incidence rate of ST/FS fractures among bisphosphonate users varies from 76 to 310 per 100,000 person-years.17 18 19 20 21 22 Most studies were conducted in western countries involving Caucasians.17 18 19 20 21

In East Asia as elsewhere, osteoporosis and osteoporotic fractures are prevalent due to aging of population,23 24 and the use of bisphosphonate to prevent and treat osteoporosis becomes increasing.22 25 26 27 28 Accordingly, bisphosphonate associated AFF is a growing concern in that area. 9 27 29

Previous studies, which were conducted in health care registry of western countries, evaluated ethnic differences of AFFs and reported that the AFF incidence was higher in Asian population than in Caucasian population.29 30 31 32 33 34 However, a recent hospital-based study showed that the AFF incidence in Korean population was not higher than those in western population.35 Therefore, the exact incidence of AFF in East Asian countries remains to be revealed. Considering the rarity of AFFs, a large epidemiologic study based on nationwide database is necessary to reveal the AFF incidence with sufficient statistical power. However, there has been no such a study conducted in East Asia.

Several studies examined the risk of AFF in long-term users of bisphosphonates. In these studies, the use of bisphosphonates was not associated with a greater risk of ST/FS fractures.17 18 20 22 Even a decreasing risk was observed with increasing average daily dose of alendronate in a nationwide cohort study from Denmark.19

Therefore, the purpose of this study was to determine the risk of ST/FS fractures and the benefit of typical hip fractures prevention among bisphosphonate users from a database on National Health Insurance Service-National Sample Cohort (NHIS-NSC).

METHODS

Data source

We conducted a retrospective cohort study, using the Korean NHIS-NSC database from 2002 to 2013.36 37 38 The NHIS-NSC database comprises a semi-dynamic cohort; data regarding newborns are added to the database every year to supplement the loss of numbers due to deaths. That database was validated by its representativeness of the overall Korean population.39 It includes data on subject demographics; clinical information, such as disease diagnosis, drug prescription, and healthcare costs; beneficiary's social economic level; and death records. Disease diagnoses held in the database are coded based on the International Codes of Disease 10th Edition Clinical Modification (ICD-10-CM).

A total of 1,107,015 subjects were randomly selected from the 756 strata using three kinds of variables (age [18 groups], gender [2 groups], and income level according to type of insurance [10 groups for both NHI district subscriber and NHI employee subscriber, and one group as medical aid: total of 21 groups]) in the Korean NHIS-NSC database.36 37

Data availability statement

The Korean NHIS-NSC database is not open to public. Its access is restricted to researchers, who gain an approval by NHIS. We got the NHIS approval and our study protocol was approved by Institutional Review Board of principal investigator's affiliation and NHIS.

Study population and design

The study cohort was defined as women patients, who were older than 50 years and had a prescription of bisphosphonates for the first time between January 1, 2003 and December 31, 2011. We excluded patients who had received that prescription during the preceding years to eliminate the influence of previous bisphosphonate treatment on the development of AFF.

We excluded patients, who had been previously treated for hip fractures (ICD-10: S720, S721, S722, S723), those, who had a diagnosis of malignancies (ICD-10: C*, D45*, D46*, D47, D470*, D471*, D472*) or metabolic bone disorders (ICD-10: M83*, Q780, Q782, E21*, E835*, G40*, M88*, N250) before the index date; the date of the first prescription of bisphosphonate (Fig. 1).

Fig. 1

Flow chart of this study.

ST = subtrochanteric, FS = femoral shaft, FN = femoral neck, IT = intertrochanteric.

We identified prescriptions of intravenous or oral forms of bisphosphonates; alendronate, risedronate, etidronate, clodronate, ibandronic acid, pamidronate and zoledronate in the NHIS-NSC database, which used the Anatomical Therapeutic Chemical classification system of the World Health Organization for the record of prescriptions.40

The duration of bisphosphonate medication was calculated as daily, weekly, monthly, quarterly and annually, considering the sustained release of prescribed bisphosphonates. To determine the continuous exposure interval, “refill gap” of up to 60 days was allowed between the end of effective period of the previous prescription and the date of next prescription.31

The long-term users were defined as subjects who had taken bisphosphonate ≥ 1 year after the index date, and subjects who had taken bisphosphonate < 1 year after the index date were grouped into the short-term users, according to the criteria of Hsiao et al.22

New bisphosphonate users were followed from the index date until the date of the first hospital admission due to ST/FS fractures or typical hip fractures, end of the study period, or subject's death, whichever came first. In our study, we treated the death as a censoring event not a competing one.

Identification of AFFs

We identified patients, who had an inpatient diagnosis of ST/FS fractures (ICD-10 codes: S722 or S723) as the primary or secondary diagnosis after the index date.

From the cohort of new bisphosphonate users, we captured their first instances of inpatient claims for ST/FS fractures after index date with the ICD 10 (S722 and S723) and codes of surgical procedures; open reduction of fractured extremity-femur, closed pinning-femur, external fixation-pelvis/femur, closed reduction of fractured extremity-pelvis/femur, and bone traction.

Identification of typical hip fractures

Typical hip fracture included femoral neck (FN) and intertrochanteric (IT) fracture as the primary or secondary diagnosis. To identify typical hip fracture, from the cohort of new bisphosphonate users, we captured their first instances of inpatient claims for FN/IT fractures after index date with the ICD 10 (S720 and S721) and codes of surgical procedures; open reduction of fractured extremity-femur, closed pinning-femur, external fixation-pelvis/femur, closed reduction of fractured extremity-pelvis/femur, bone traction, hemiarthroplasty, and total hip arthroplasty.

Potential confounders

In the analysis, we included age at the index date and Charlson's index of comorbidities, which were diagnosed within 1 year before the index date, as confounding factors.

Statistical analysis

The demographic and clinical information between long-term users and short-term users was compared by descriptive statistics. Categorical variables were described by frequency and continuous variables by mean and standard deviation.

We calculated the incidence rates per 100,000 person-years by dividing the number of events by the total number of person years at risk for the ST/FS and for FN/IT fractures. We also calculated the 95% confidence interval (CI) assuming a Poisson distribution.

Cox regression models were used to estimate hazard ratios (HRs) and their 95% CIs for ST/FS and FN/IN fractures with time adjusting covariates. Adjustments were made for age and Charlson's comorbidity index score. By using this model, we could obtain an estimate of the HR of bisphosphonate use for ST/FS fractures and the protective benefit of bisphosphonate use for FN/IN fracture.

We also plotted the cumulative incidence of ST/FS and FN/IT in each group.

To determine the risk and benefit of bisphosphonate, absolute risk increase and number needed to harm (NNH) for ST/FS, and absolute risk reduction and number needed to treat (NNT) for typical hip fracture were calculated.

We used the SAS statistical application program (release 9.4; SAS Institute, Cary, NC, USA) for all statistical analyses. A two-tailed value of P < 0.05 was considered to be statistically significant.

Ethics statement

This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital (B-1103/124-102). Informed consent was waived, because the data was anonymized, so study was considered exempt from review.

RESULTS

From the 551,556 eligible women, who were included in the Korean NHIS-NSC database from 2002 to 2013, we identified 46,420 bisphosphonate users who received prescriptions for at least one bisphosphonate. Among them, 36,529 people met the inclusion criteria (Fig. 1).

After calculating duration of bisphosphonate use, 14,689 users were selected as long-term users (≥ 1 year) and 21,840 people were defined as short-term users (< 1 year) (Fig. 1). Table 1 shows the baseline characteristics of long-term and short-term users.

Table 1

Demographics of bisphosphonate long-term users and short-term users

Variables		Long-term users (n = 14,689)	Short-term users (n = 21,840)	P value
Age group, yr				< 0.001
	50–54	1,001 (6.8)	1,733 (7.9)
	55–59	1,963 (13.4)	2,606 (11.9)
	60–64	2,732 (18.6)	3,056 (14.0)
	65–69	3,796 (25.8)	4,523 (20.7)
	70–74	2,867 (19.5)	4,001 (18.3)
	75–79	1,554 (10.6)	3,139 (14.4)
	80–84	589 (4.0)	1,831 (8.4)
	≥ 85	187 (1.3)	951 (4.4)
Myocardial infarction		79 (0.5)	138 (0.6)	0.251
Congestive heart failure		353 (2.4)	603 (2.8)	0.036
Peripheral vascular disease		978 (6.7)	1,578 (7.2)	0.037
Cerebrovascular disease		1,214 (8.3)	1,875 (8.6)	0.280
Dementia		165 (1.1)	456 (2.1)	< 0.001
Chronic pulmonary disease		3,051 (20.8)	4,634 (21.2)	0.304
Rheumatologic disease		1,065 (7.3)	1,090 (5.0)	< 0.001
Peptic ulcer disease		3,072 (20.9)	4,030 (18.5)	< 0.001
Mild liver disease		1,054 (7.2)	1,399 (6.4)	0.004
Diabetes without chronic complication		1,415 (9.6)	2,382 (10.9)	< 0.001
Diabetes with chronic complication		837 (5.7)	1,288 (5.9)	0.425
Hemiplegia		73 (0.5)	143 (0.7)	0.054
Renal disease		50 (0.3)	109 (0.5)	0.024
Moderate or severe liver disease		14 (0.1)	30 (0.1)	0.256
Charlson's comorbidity index		0.98 ± 1.15	0.98 ± 1.16	0.803
Follow-up duration, mon		75.0 ± 29.9	63.8 ± 30.1	< 0.001

Data are presented as number (%) or mean ± standard deviation.

During the study period, 61 of the long-term users had ST/FS fractures, while 36 of the short-term users had such fractures. The incidence rate of ST/FS fractures was 67.1/100,000 person-years (95% CI, 50.3–83.9) in the long-term users and 31.2/100,000 person-years (95% CI, 21.0–41.4) in the short-term users. The cumulative incidence of ST/FS fracture was higher in the long-term users than in the short-term users (P < 0.001) (Fig. 2).

Fig. 2

Cumulative incidence of subtrochanteric/femoral shaft fractures between bisphosphonate long-term users and short-term users.

The risk of ST/FS fractures was higher in long-term users than in short-term users (adjusted HR, 2.345; 95% CI, 1.541–3.569) (Table 2).

Table 2

HRs for subtrochanteric and femoral shaft fracture

Variables		HR	95% CI		P value
Variables		HR	Lower	Upper	P value
CCI		1.08	0.86	1.21	0.837
Age group, yr
	50–54	Reference
	55–59	3.80	0.47	30.93	0.211
	60–64	3.49	0.44	27.54	0.236
	65–69	6.76	0.91	50.10	0.062
	70–74	7.35	0.98	54.97	0.052
	75–79	16.51	2.23	122.19	0.006
	80–84	20.28	2.63	156.37	0.004
	≥ 85	10.31	0.93	114.25	0.057
Group
	Short-term user	Reference
	Long-term use	2.35	1.54	3.57	< 0.001

HR = hazard ratio, CI = confidence interval, CCI = Charlson's comorbidity index.

During the study period, 204 of the long-term users had FN/IT fractures, while 511 of the short-term users had such fractures. The incidence rate of FN/IT fractures was 225.5/100,000 person-years (95% CI, 194.6–256.5) in the long-term users and 448.6/100,000 person-years (95% CI, 409.7–487.5) in the short-term users. The cumulative incidence of FN/IT fractures was higher in the short-term users than in the long-term users (P < 0.001) (Fig. 3).

Fig. 3

Cumulative incidence of femoral neck/intertrochanteric fractures between bisphosphonate long-term users and short-term users.

Using the short-term users as a reference, long-term use significantly reduced the risk of typical hip fracture (adjusted HR, 0.578; 95% CI, 0.490–0.682) (Table 3).

Table 3

HRs for femoral neck and intertrochanteric fracture

Variables		HR	95% CI		P value
Variables		HR	Lower	Upper	P value
CCI		1.21	1.15	1.28	< 0.001
Age group, yr
	50–54	Reference
	55–59	1.41	0.50	3.99	0.522
	60–64	5.10	2.04	12.71	< 0.001
	65–69	7.63	3.12	18.66	< 0.001
	70–74	12.97	5.32	31.59	< 0.001
	75–79	22.42	9.22	54.56	< 0.001
	80–84	35.34	14.46	86.40	< 0.001
	≥ 85	36.67	14.58	92.20	< 0.001
Group
	Short-term user	Reference
	Long-term use	0.58	0.49	0.68	< 0.001

HR = hazard ratio, CI = confidence interval, CCI = Charlson's comorbidity index.

Absolute risk increase for ST/FS was 0.0025 (61/14,689–36/21,840) and the NNH for ST/FS was 400, which mean that one ST/FS will occur if 400 patients were treated with long-term use of bisphosphonate. Absolute risk reduction for typical hip fracture was 0.0095 (511-21,840 - 204/14,689) and the NNT for typical hip fracture was 105, which mean that 105 patients would have to be treated with long-term bisphosphonate to avoid one typical hip fracture.

DISCUSSION

In this population-based cohort study using diagnostic and procedure codes, we found out the association between the long-term use of bisphosphonate and the risk of ST/FS fractures. However, our results showed that the long-term use of bisphosphonate (≥ 1 year) was associated with the reduced risk of FN/IT fractures.

The incidence rate of ST/FS fractures was 67.1/100,000 person-years, which was comparable with or lower than reportedly known rates in western countries (Table 4).17 20 22

Table 4

Incidence rate of subtrochanteric and femoral shaft fracture identified using code system after bisphosphonate use

Authors	Country	Study period	Age, yr	No. of bisphosphonate users	Incidence rate (/100,000 patients-yr)
Abrahamsen et al.17	Denmark	1997–2005	> 60	5,187^a	280
Abrahamsen et al.18	Denmark	1996–2005	NA	39,567^a	310
Hsiao et al.22	Taiwan	2001–2007	NA	2,425^a	155
Kim et al.20	USA	1996–2006	NA	17,028	146
Wang et al.21	USA	2006–2010	> 65	522,287	76
Current study	Korea	2003–2011	> 50	14,689	67.1

NA = not applicable.

^aAlendronate users.

The estimated incidence rate might be overestimated in our study because we could not exclude high energy fractures by using ICD-10 codes. Nevertheless, we observed a much lower incidence rate of ST/FS fractures in Korea than those of western countries (Table 4).17 20 22

Our results were not consistent with those of previous studies, which reported that the occurrence of ST/FS fractures was higher in Asian than Caucasian.29 30 31 32 33 34

Several studies reported that the use of bisphosphonate was not associated with an increased risk of AFFs,17 18 19 20 22 while other studies have demonstrated that the occurrence of those fractures was significantly associated with the long-term use of bisphosphonate.7 17 20 21 22 29 41 42 Our study showed that the long-term use of bisphosphonate (≥ 1 year) was a potential risk factor of ST/FS fractures.

On the other hand, many clinical trials and registry-based cohort studies have reported that bisphosphonate use provides benefits of hip fracture prevention.26 43 Several guidelines on osteoporosis treatment have recommended use of bisphosphonate to prevent osteoporotic fractures.44 45 46 47 Our results supported these guidelines and those studies on benefits of bisphosphonate on fracture prevention.

Our results, the difference between NNH (400) for ST/FS and NNT (105) for typical hip fracture, mean that just one ST/FS could occur, while 4 typical hip fractures would be prevented, if 400 patient was treated with long-term bisphosphonate. Our findings showed that the benefit of long-term use of bisphosphonate for prevention of typical hip fracture was larger than the risk for ST/FS.

Our study has several strengths. First, our cohort was one of the largest from Asian, allowing us to investigate even rare events such as AFFs. Second, we conducted population-based study design using a nationwide claims database containing drug prescriptions.

There were several limitations in this study. First, although we used a very large cohort, our cohort was a sampled one and might not have represented the entire female population in Korea. However, the Korean government provided a standardized cohort by using stratification according to the age, gender, and level of socioeconomic status. Second, we could not evaluate radiographs to confirm the atypical features of ST/FS fractures. This study might have a potential bias due to inaccurate coding and incomplete medical records.48 However, previous several studies on the epidemiology of AFFs have used the same coding system.17 18 19 20 21 22 A evaluation for the validity of discharged diagnosis showed that the overall positive predictive value of the diagnoses was 83.4% in patients, who were admitted to hospital.49 Third, we could not analyze possible confounding factors such as menopausal status, bone turnover status, and bone mineral density, because the claim database did not include these. Fourth, fracture due to high-energy injury might be included in this study, because the ICD-10 coding system did not distinguish between high and low-energy fractures. However, we did not need an additional operational definition to exclude high energy trauma, because the NHIS database does not include high-energy injuries such as those from traffic accidents and industrial injury.50

Despite these limitations, our results showed that bisphosphonates may be playing a differential role between FN/IT fracture and ST/FS fracture. The longer use of bisphosphonate was associated with the lower risk of typical hip fracture, while it was associated with the higher risk of occurrence of ST/FS fractures in Korean women. Our study suggested that the raised concerns about bisphosphonate-associated ST/FS fractures in East Asia may be overestimated than the reality, considering the longer use of bisphosphonate was associated with the lower risk of FN/IT fractures.

ACKNOWLEDGMENTS

This study used National Health Information Database (NHIS-2017-2-392) made by National Health Insurance Service (NHIS). The author(s) declare no conflict of interest with NHIS. National Health Information Database was provided by the National Health Insurance Service (NHIS) of Korea. The authors would like to thank the National Health Insurance Service for cooperation.

Notes

Funding: This study was supported by the grant (KOHTERF-2017-01) from Korean Human Technology Research Foundation and the grant (No. 13-2017-009) from SNUBH Research Fund.

Disclosure: The authors have no potential conflicts of interest to disclose.

Author Contributions:

Conceptualization: Lee YK.
Data curation: Ahn S, Ji E.
Formal analysis: Ahn S, Ji E.
Methodology: Ji E.
Writing - original draft: Won S, Park JW, Kim JK, Lee YK.
Writing - review & editing: Lee YK, Ahn A, Ji E, Won S.

References

1. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA. 2001; 285(11):1415–1418. PMID: 11255400.

2. Levinson W, Altkorn D. Primary prevention of postmenopausal osteoporosis. JAMA. 1998; 280(21):1821–1822. PMID: 9846765.

3. Cappola AR, Shoback DM. Osteoporosis therapy in postmenopausal women with high risk of fracture. JAMA. 2016; 316(7):715–716. PMID: 27533154.

4. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001; 286(22):2815–2822. PMID: 11735756.

5. Pfister AK, Trotter CC. Bisphosphonate use and femoral fractures in older women. JAMA. 2011; 305(20):2068–2069.

6. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010; 304(13):1480–1484. PMID: 20924014.

7. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011; 305(8):783–789. PMID: 21343577.

8. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res. 2011; 26(3):553–560. PMID: 20814954.

9. Lee YK, Ha YC, Park C, Yoo JJ, Shin CS, Koo KH. Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int. 2013; 24(2):707–711. PMID: 22618268.

10. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014; 29(1):1–23. PMID: 23712442.

11. Gustafsson A, Schilcher J, Grassi L, Aspenberg P, Isaksson H. Strains caused by daily loading might be responsible for delayed healing of an incomplete atypical femoral fracture. Bone. 2016; 88:125–130. PMID: 27113528.

12. Teo BJ, Koh JS, Goh SK, Png MA, Chua DT, Howe TS. Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Joint J. 2014; 96-B(5):658–664. PMID: 24788502.

13. Egol KA, Park JH, Rosenberg ZS, Peck V, Tejwani NC. Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res. 2014; 472(9):2728–2734. PMID: 23604648.

14. Prasarn ML, Ahn J, Helfet DL, Lane JM, Lorich DG. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res. 2012; 470(8):2295–2301. PMID: 22669553.

15. Schilcher J. High revision rate but good healing capacity of atypical femoral fractures. A comparison with common shaft fractures. Injury. 2015; 46(12):2468–2473. PMID: 26477344.

16. Bogdan Y, Tornetta P 3rd, Einhorn TA, Guy P, Leveille L, Robinson J, et al. Healing time and complications in operatively treated atypical femur fractures associated with bisphosphonate use: a multicenter retrospective cohort. J Orthop Trauma. 2016; 30(4):177–181. PMID: 26709814.

17. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res. 2009; 24(6):1095–1102. PMID: 19113931.

18. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab. 2010; 95(12):5258–5265. PMID: 20843943.

19. Vestergaard P, Schwartz F, Rejnmark L, Mosekilde L. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int. 2011; 22(3):993–1001. PMID: 21165600.

20. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011; 26(5):993–1001. PMID: 21542002.

21. Wang Z, Ward MM, Chan L, Bhattacharyya T. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries. Osteoporos Int. 2014; 25(8):2109–2116. PMID: 24846316.

22. Hsiao FY, Huang WF, Chen YM, Wen YW, Kao YH, Chen LK, et al. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women. Clin Ther. 2011; 33(11):1659–1667. PMID: 22018450.

23. Ha YC, Kim TY, Lee A, Lee YK, Kim HY, Kim JH, et al. Current trends and future projections of hip fracture in South Korea using nationwide claims data. Osteoporos Int. 2016; 27(8):2603–2609. PMID: 27112763.

24. Kim TY, Jang S, Park CM, Lee A, Lee YK, Kim HY, et al. Trends of incidence, mortality, and future projection of spinal fractures in Korea using Nationwide Claims Data. J Korean Med Sci. 2016; 31(5):801–805. PMID: 27134505.

25. Choi HJ, Shin CS, Ha YC, Jang SM, Jang SH, Park CM, et al. Burden of osteoporosis in adults in Korea: a national health insurance database study. J Bone Miner Metab. 2012; 30(1):54–58. PMID: 21633927.

26. Lee YK, Ha YC, Choi HJ, Jang S, Park C, Lim YT, et al. Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int. 2013; 24(11):2887–2892. PMID: 23681088.

27. Ha YC, Lee YK, Lim YT, Jang SM, Shin CS. Physicians' attitudes to contemporary issues on osteoporosis management in Korea. J Bone Metab. 2014; 21(2):143–149. PMID: 25006571.

28. Lee YK, Jang S, Ha YC. Management of osteoporosis in South Korea. Crit Rev Eukaryot Gene Expr. 2015; 25(1):33–40. PMID: 25955816.

29. Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012; 27(12):2544–2550. PMID: 22836783.

30. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010; 47(2):169–180. PMID: 20493982.

31. Lo JC, Huang SY, Lee GA, Khandelwal S, Provus J, Ettinger B, et al. Clinical correlates of atypical femoral fracture. Bone. 2012; 51(1):181–184. PMID: 22414379.

32. Marcano A, Taormina D, Egol KA, Peck V, Tejwani NC. Are race and sex associated with the occurrence of atypical femoral fractures? Clin Orthop Relat Res. 2014; 472(3):1020–1027. PMID: 24166075.

33. Soh HH, Chua IT, Kwek EB. Atypical fractures of the femur: effect of anterolateral bowing of the femur on fracture location. Arch Orthop Trauma Surg. 2015; 135(11):1485–1490. PMID: 26286640.

34. Chen LP, Chang TK, Huang TY, Kwok TG, Lu YC. The correlation between lateral bowing angle of the femur and the location of atypical femur fractures. Calcif Tissue Int. 2014; 95(3):240–247. PMID: 24980895.

35. Lee YK, Ahn S, Kim KM, Suh CS, Koo KH. Incidence rate of atypical femoral fracture after bisphosphonates treatment in Korea. J Korean Med Sci. 2018; 33(5):e38. PMID: 29349947.

36. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017; 46(2):e15. PMID: 26822938.

37. Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017; 46(3):799–800. PMID: 27794523.

38. Korean National Health Insurance Service. Sample research DB. Updated 2015. Accessed May 31, 2017. http://nhiss.nhis.or.kr/bd/ab/bdaba022eng.do.

39. Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health. 2014; 36:e2014008. PMID: 25078381.

40. Jung SY, Sohn HS, Park EJ, Suh HS, Park JW, Kwon JW. Oral bisphosphonates and upper gastrointestinal cancer risks in Asians with osteoporosis: a nested case-control study using national retrospective cohort sample data from Korea. PLoS One. 2016; 11(3):e0150531. PMID: 26937968.

41. Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009; 80(4):413–415. PMID: 19568963.

42. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011; 364(18):1728–1737. PMID: 21542743.

43. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799–1809. PMID: 17878149.

44. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016--executive summary. Endocr Pract. 2016; 22(9):1111–1118. PMID: 27643923.

45. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013; 8(1-2):136. PMID: 24113837.

46. Wang CC, Wu CH, Farley JF. Patterns of pharmacological treatment for osteoporosis among patients qualified for pharmacotherapy according to the national osteoporosis foundation guidelines. Ann Pharmacother. 2015; 49(9):995–1003. PMID: 26041809.

47. Compston J. NOGG and NICE: new guidelines and quality standards for osteoporosis. Maturitas. 2017; 106:97–98. PMID: 28803757.

48. Narongroeknawin P, Patkar NM, Shakoory B, Jain A, Curtis JR, Delzell E, et al. Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data. J Clin Densitom. 2012; 15(1):92–102. PMID: 22071028.

49. Park BJ, Sung JH, Park KD, Seo SW, Kim S. Report of the Evaluation for Validity of Discharged Diagnoses in Korean Health Insurance Database. Seoul: Seoul National University;2003.

50. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2017; 46(2):e15. PMID: 26822938.

TOOLS

Similar articles